ReviewNature reviews. Nephrology2025
Risk-directed management of chronic kidney disease.
Review in Nature reviews. Nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Gut microbiota biomarkers of chronic kidney disease progression identified by 16S rDNA sequencing and machine learning.Renal failure · 2026Article
- MERWACS: Development and external validation of a non-invasive machine learning tool for identifying subjects to be screened for CKD.PLOS digital health · 2026Article
- Dynamically predicting renal failure after development of diabetes across biobanks.PLOS digital health · 2026Article
- Multifactorial chronic kidney disease and the kidney capacity-workload balance.Nature reviews. Nephrology · 2026Review
- Guideline-Directed Medical Therapies for Diabetic Kidney Disease Among Thai People With Type 2 Diabetes: A Real-World Data Based on Theptarin Diabetes Staging.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Circulating Extracellular Vesicle MicroRNAs as Predictive Biomarkers for Kidney and Cardiovascular Events.Journal of the American Heart Association · 2026Article
- Gut microbial-derived metabolites: key players in kidney disease and renal fibrosis.International journal of biological sciences · 2026Review
- Urine as a source of biomarkers and biological knowledge in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- The overlap of ANCA associated vasculitis with Sjögren's syndrome in elderly male patient: a case report and literature review.Frontiers in medicine · 2026Article
- An interpretable nomogram with SHAP analysis predicts thrombotic failure of forearm arteriovenous fistulas.Frontiers in surgery · 2026Article
- Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.Drug design, development and therapy · 2026Article
- Association between night shift work, genetic risk, and chronic kidney disease: a prospective cohort study based on the UK Biobank.Frontiers in public health · 2026Article
- Development of a nomogram for predicting incident heart failure and all-cause mortality in patients with chronic kidney disease: a 3-year follow-up study.Frontiers in medicine · 2026Article
- Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026Review
- Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.Journal of the American Society of Nephrology : JASN · 2025 · on this mapReview
- Association of In Vivo Kidney Stiffness Measured by Multifrequency MR Elastography and Long-Term Renal Function in Transplant Recipients and Living Donors.Journal of magnetic resonance imaging : JMRI · 2025Article
- Efficacy and safety of Guben Tongluo formula in treating chronic kidney disease (stage G3): a multicenter randomized controlled clinical trial.Frontiers in medicine · 2025Article
- Multi-Center Health Informatics to Examine the Implementation of Guideline-Directed Medical Therapy in Chronic Kidney Disease.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The timely and rational institution of therapy is a key step towards reducing the global burden of chronic kidney disease (CKD). CKD is a heterogeneous entity with varied aetiologies and diverse trajectories, which include risk of kidney failure but also cardiovascular events and death. Developments in the past decade include substantial progress in CKD risk prediction, driven in part by the accumulation of electronic health records data. In addition, large randomized clinical trials have demonstrated the effectiveness of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor antagonists in reducing adverse events in CKD, greatly expanding the options for effective therapy. Alongside angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, these classes of medication have been proposed to be the four pillars of CKD pharmacotherapy. However, all of these drug classes are underutilized, even in individuals at high risk. Leveraging prognostic estimates to guide therapy could help clinicians to prescribe CKD-related therapies to those who are most likely to benefit from their use. Risk-based CKD management thus aligns patient risk and care, allowing the prioritization of absolute benefit in determining therapeutic selection and timing. Here, we discuss CKD prognosis tools, evidence-based management and prognosis-guided therapies.
Indexed as
Identifiers
39885336What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.